CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced positive two-year results from the Phase 3 MAESTRO-NAFLD-1 trial, demonstrating the potential of Rezdiffra (resmetirom) to significantly reduce liver stiffness in patients with compensated MASH cirrhosis (F4c), a critical marker for liver disease progression.
Patients in the open-label arm of the study achieved an average 6.7 kPa reduction in liver stiffness, as measured by vibration-controlled transient elastography (VCTE). This reduction represents the largest improvement reported in this patient population to date. Furthermore, 51% of participants achieved at least a 25% reduction in liver stiffness, an improvement associated with lower risks of advancing to end-stage liver disease.
“These data demonstrating patients with compensated MASH cirrhosis achieved marked reductions in VCTE are highly encouraging,” said Mazen Noureddin, M.D., M.H.Sc., a leading liver disease expert. “A mean 6.7 kPa reduction suggests many patients are moving into lower risk categories for liver-related events.”
Rezdiffra exhibited a safety profile consistent with previous clinical trials, with low discontinuation rates due to adverse events. Becky Taub, M.D., Chief Medical Officer and President of Research & Development at Madrigal, emphasized the urgency of addressing MASH cirrhosis, noting, “Patients with MASH who progress to cirrhosis face a 42-times higher risk of liver-related mortality. These new data reinforce our confidence in the ongoing MAESTRO-NASH OUTCOMES trial, which could position Rezdiffra as the first approved therapy for F2-F4c MASH.”
The ongoing MAESTRO-NASH OUTCOMES trial is evaluating the progression to liver complications in patients treated with Rezdiffra compared to a placebo. A positive outcome could pave the way for full approval and establish Rezdiffra as a groundbreaking option for treating this underserved patient population.
Madrigal plans to present additional findings from the MAESTRO-NAFLD-1 trial at an upcoming medical conference, continuing its commitment to advancing care for MASH patients.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.